Drug profile

The FDA adverse-event record for Praziquantel, Pyrantel Pamoate & Febantel

76 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Praziquantel, Pyrantel Pamoate & Febantel. See the species affected, top reactions, and outcomes below.

76
adverse-event reports
3.9%
death-coded share
Dog
most-reported species
16
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
76
Total Reports
3
Deaths Reported
3.9%
Death Rate

Active Ingredients

Praziquantel, Pyrantel Pamoate & Febantel

Administration Routes

OralUnknown

Species Affected

Dog 68
Cat 8

Most Affected Breeds

Greyhound 10
Shepherd Dog - German 7
Retriever - Labrador 7
Crossbred Canine/dog 5
Domestic Shorthair 5
Shih Tzu 4
Terrier - Yorkshire 3
Terrier - Bull - American Pit 3
Shepherd Dog - Australian 3
Chihuahua 2

Most Reported Reactions

Vomiting 16
Lack of efficacy (endoparasite) - NOS 15
Lethargy (see also Central nervous system depression in 'Neurological') 12
Ataxia 8
Anorexia 6
Diarrhoea 6
Decreased appetite 5
Fever 5
Lack of efficacy (endoparasite) - hookworm 5
Seizure NOS 4
Behavioural disorder NOS 4
Nystagmus 4

Outcome Breakdown

Ongoing
52 (68.4%)
Recovered/Normal
18 (23.7%)
Outcome Unknown
3 (3.9%)
Died
2 (2.6%)
Euthanized
1 (1.3%)

Praziquantel, Pyrantel Pamoate & Febantel Adverse Event Insights

76 reports name Praziquantel, Pyrantel Pamoate & Febantel; 3 recorded a death outcome (3.9% of reported events, not a population-level mortality rate). Active ingredient: Praziquantel, Pyrantel Pamoate & Febantel. Administration routes: Oral, Unknown.

By species: Dog (68 reports), Cat (8 reports). By breed: Greyhound (10), Shepherd Dog - German (7), Retriever - Labrador (7).

Leading clinical signs: Vomiting (16), Lack of efficacy (endoparasite) - NOS (15), Lethargy (see also Central nervous system depression in 'Neurological') (12), Ataxia (8). Outcome, 76 coded reports: Ongoing leads at 68.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.